These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29191785)

  • 1. Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors.
    Gazzano E; Rolando B; Chegaev K; Salaroglio IC; Kopecka J; Pedrini I; Saponara S; Sorge M; Buondonno I; Stella B; Marengo A; Valoti M; Brancaccio M; Fruttero R; Gasco A; Arpicco S; Riganti C
    J Control Release; 2018 Jan; 270():37-52. PubMed ID: 29191785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
    Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C
    Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation.
    Alibolandi M; Abnous K; Sadeghi F; Hosseinkhani H; Ramezani M; Hadizadeh F
    Int J Pharm; 2016 Mar; 500(1-2):162-78. PubMed ID: 26802496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An all-in-one nanoparticle for overcoming drug resistance: doxorubicin and elacridar co-loaded folate receptor targeted PLGA/MSN hybrid nanoparticles.
    Tonbul H; Şahin A; Öztürk SC; Ultav G; Tavukçuoğlu E; Akbaş S; Aktaş Y; Esendağlı G; Çapan Y
    J Drug Target; 2024 Nov; 32(9):1101-1110. PubMed ID: 38946465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
    Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
    J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer.
    Füredi A; Szebényi K; Tóth S; Cserepes M; Hámori L; Nagy V; Karai E; Vajdovich P; Imre T; Szabó P; Szüts D; Tóvári J; Szakács G
    J Control Release; 2017 Sep; 261():287-296. PubMed ID: 28700899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
    Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
    J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
    Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
    Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor.
    Lee ES; Na K; Bae YH
    J Control Release; 2005 Mar; 103(2):405-18. PubMed ID: 15763623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
    Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
    J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folate receptor-targeted liposomal nanocomplex for effective synergistic photothermal-chemotherapy of breast cancer in vivo.
    Nguyen VD; Min HK; Kim CS; Han J; Park JO; Choi E
    Colloids Surf B Biointerfaces; 2019 Jan; 173():539-548. PubMed ID: 30343218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-pH Sensitive Charge-Reversal Drug Delivery System for Highly Precise and Penetrative Chemotherapy.
    Chen W; Li J; Xing Y; Wang X; Zhang H; Xia M; Wang D
    Pharm Res; 2020 Jul; 37(7):134. PubMed ID: 32642819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes.
    Malhi SS; Budhiraja A; Arora S; Chaudhari KR; Nepali K; Kumar R; Sohi H; Murthy RS
    Int J Pharm; 2012 Aug; 432(1-2):63-74. PubMed ID: 22531856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein.
    Abd-Ellatef GEF; Gazzano E; El-Desoky AH; Hamed AR; Kopecka J; Belisario DC; Costamagna C; S Marie MA; Fahmy SR; Abdel-Hamid AZ; Riganti C
    Pharmacol Res; 2022 Jan; 175():105975. PubMed ID: 34785319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, preparation, and in vitro characterization of a trimodally-targeted nanomagnetic onco-theranostic system for cancer diagnosis and therapy.
    Zarrin A; Sadighian S; Rostamizadeh K; Firuzi O; Hamidi M; Mohammadi-Samani S; Miri R
    Int J Pharm; 2016 Mar; 500(1-2):62-76. PubMed ID: 26721723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein.
    Riganti C; Gazzano E; Gulino GR; Volante M; Ghigo D; Kopecka J
    Cancer Lett; 2015 May; 360(2):219-26. PubMed ID: 25681670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
    Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
    Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Theranostic pH-sensitive nanoparticles for highly efficient targeted delivery of doxorubicin for breast tumor treatment.
    Pan C; Liu Y; Zhou M; Wang W; Shi M; Xing M; Liao W
    Int J Nanomedicine; 2018; 13():1119-1137. PubMed ID: 29520140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.